Lv1
80 积分 2024-04-01 加入
Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)
5天前
已完结
Preclinical Safety Evaluation of Recombinant Human Interleukin-10
3个月前
已完结
Cancer vaccines: the next immunotherapy frontier
4个月前
已完结
CAR T cells put the brakes on asthma
4个月前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
5个月前
已完结
CD45 threads the needle of cytokine cancer immunotherapy
5个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
5个月前
已关闭
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
5个月前
已关闭
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
5个月前
已关闭
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
10个月前
已完结
皖公网安备34019202002308
